Ielmag3 (Buffered Phosphate Solution | Mertiatide)

Mertiatide provides phosphate ions in a buffered form, helping to maintain extracellular phosphate concentrations and physiological pH during infusion. The supplied phosphate can be incorporated into cellular metabolic pathways, supporting processes that rely on phosphate, such as energy production and signal transduction.

The dosage of Ielmag3 is determined by the prescribing clinician based on the specific clinical context, patient characteristics, and intended use. Healthcare professionals calculate the appropriate volume and rate of infusion according to established protocols and laboratory monitoring.

Safety data for Mertiatide in pregnant or lactating individuals are limited. Because the product is an intravenous phosphate solution, clinicians should weigh potential benefits against unknown risks and consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ielmag3 is formulated as a buffered phosphate solution for intravenous use, offering controlled pH and phosphate delivery. Compared with non‑buffered phosphate preparations, it may provide more stable infusion characteristics, but clinical choice depends on the specific protocol, compatibility with other IV agents, and institutional preferences.

Ielmag3 should be stored at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct sunlight, and avoid freezing. Inspect the solution for particulate matter before use.

Ielmag3 is administered intravenously by a qualified healthcare professional. The solution is typically infused over a controlled period, with dosing and infusion rate determined by the prescriber and guided by laboratory monitoring of serum phosphate and related electrolytes.

Serious risks include severe hyperphosphatemia, which can lead to calcium‑phosphate precipitation, allergic reactions ranging from rash to anaphylaxis, hypocalcemia, and potential worsening of renal function in susceptible patients. Continuous monitoring of electrolytes is essential.

Ielmag3 is contraindicated in patients with known severe hyperphosphatemia, uncontrolled calcium overload, or a documented allergy to phosphate solutions. Caution is advised for individuals with impaired renal function, as they may be at higher risk for phosphate accumulation.